



## LETTER TO THE EDITOR

### Response to the Letter to the Editor “When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry”



### Resposta à Carta ao Editor «Quando o sacubitril/valsartan encontra a neprilisin e o peptídeo natriurético auricular tipo B no labirinto da bioquímica»

We read with interest the letter by Siniorakis et al. referring to our paper, “Sacubitril/valsartan: a practical guide” published in the *Journal*,<sup>1</sup> and we do agree that biochemical issues on natriuretic peptides in the context of sacubitril/valsartan treatment are complex and controversial. Nevertheless, we have to keep in mind that our purpose was to provide physicians with clear and practical guidance to everyday practice, and our recommendations are based on the evidence of clinical arguments.

There is ample literature about the effects of neprilysin and its inhibition by neprilysin inhibitors like sacubitril on the natriuretic peptide system – protein modifications, endopeptide scissions – and their identification by immunoassays from different manufacturers. The effects of neprilysin inhibition are variable and poorly predictable in BNP assays from different manufacturers; change in one BNP assay may not necessarily be comparable to another one and there is definitely heterogeneity across assays with respect to how much change is observed. This variation is logical because neprilysin cleaves the BNP molecule in several places, which also reflect binding sites for the various BNP immunoassays. Sacubitril/valsartan leads to a somewhat more predictable decrease in NT-proBNP, as measured by different assays.<sup>2</sup>

There is also wide between-patient variability in BNP response to sacubitril/valsartan, including the initial variable increase in BNP after initiation of the ARNi in HFREF patients – no increase in BNP in some patients, variable increases in others – compared to a more homogeneous NT-proBNP decrease.<sup>3,4</sup>

Because of these two effects, investigators recommend the use of NT-proBNP after sacubitril/valsartan initiation to avoid clinical confusion. This is reflected in the 2017 American College of Cardiology expert consensus decision pathway for optimization of heart failure (HF) treatment and in the 2019 Heart Failure Association practical guidance on the use of natriuretic peptides. The Task Forces consider NT-proBNP “the preferred biomarker to quantify HF severity and monitor prognosis in patients on sacubitril/valsartan”.<sup>5–7</sup>

Moreover, the European Medicines Agency package clearly states that BNP is not a suitable biomarker of HF in patients treated with sacubitril/valsartan because BNP is a neprilysin substrate. NT-proBNP is not a neprilysin substrate and is therefore a more suitable biomarker.<sup>8,9</sup>

The US Food and Drug Administration has recently approved sacubitril/valsartan in pediatric HF based on its effect on NT-proBNP levels; NT-proBNP is therefore considered a valid surrogate efficacy endpoint for regulatory approval of sacubitril/valsartan.<sup>10</sup>

Therefore, although we do understand the biochemical issues reported by Siniorakis et al., our practical recommendation may be more prudent and probably limit clinical confusion, at least until BNP reaches a steady state during the maintenance phase of ARNi treatment.<sup>4</sup> However, in hospitals where BNP is the only natriuretic peptide assay available, its measurement during maintenance treatment with sacubitril/valsartan reliably reflects clinical prognosis with comparable performance to NT-proBNP. BNP should not however be used to determine treatment adherence or degree of treatment response, or lack thereof, in individual patients, during the initial phases of treatment.<sup>4</sup>

The response of natriuretic peptides to sacubitril/valsartan and comparisons of different BNP and NT-proBNP assays that target different regions on the BNP molecule, as well as NT-proBNP and proBNP1–108 assays, have been prospectively tested in PROVE-HF, and should provide a more comprehensive picture.<sup>11,12</sup> Until then, our practical recommendation is consistent with current international guidelines and expert consensus statements.

## References

1. Fonseca C, Brito D, Ferreira J, et al. Sacubitril/valsartan: A practical guide. *Rev Port Cardiol*. 2019; <http://dx.doi.org/10.1016/j.repc.2018.10.008>.

DOI of original article: <https://doi.org/10.1016/j.repc.2019.04.011>

<https://doi.org/10.1016/j.repc.2020.03.010>

0870-2551/© 2020 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2. Ibrahim NE, McCarthy CP, Shrestha S, et al. Effect of neprilysin inhibition on various natriuretic peptide assays. *J Am Coll Cardiol.* 2019;73:1273–84.
3. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. *Circulation.* 2015;131:54–61.
4. Myhre PL, Vaduganathan M, Claggett B, et al. B-Type Natriuretic Peptide during treatment with sacubitril/valsartan The PARADIGM-HF trial. *J Am Coll Cardiol.* 2019;73:1264–72.
5. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017ACC Expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol.* 2018;71:201–30.
6. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation.* 2017;136:e137–61.
7. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. *Eur J Heart Fail.* 2019;21:715–31.
8. [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004062/human\\_med\\_001929.jsp&mid=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004062/human_med_001929.jsp&mid=WC0b01ac058001d124).
9. Early;1; Access to Medicines Scheme – Treatment protocol – Information for healthcare professionals, LCZ696. EAMS NUMBER 00101/0002. Accessed online 09-Sep-2015: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/457858/EAMS\\_Sacubitril-valsartan\\_Treatment\\_protocol\\_-\\_information\\_for\\_HCP.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/457858/EAMS_Sacubitril-valsartan_Treatment_protocol_-_information_for_HCP.pdf).
10. <https://www.pharma.us.novartis.com/news/media-releases/novartis-entresto-receives-fda-approval-pediatric-heart-failure-helping-address>.
11. Januzzi JL, Butler J, Fombu E, et al. Rationale and methods of the prospective study of biomarkers, symptom improvement, and ventricular remodeling during sacubitril/valsartan therapy for heart failure (PROVE-HF) et al. *Am Heart J.* 2018;199:130–6.
12. PROVE-HF, Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. *JAMA.* 2019;322:95–1085.

Cândida Fonseca\*, Dulce Brito, Jorge Ferreira,  
Fátima Franco, João Morais, José Silva Cardoso

*Clínica de Insuficiência cardíaca, Hospital São Francisco Xavier – Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal*

\* Corresponding author.

E-mail address: [mcandidafonseca@gmail.com](mailto:mcandidafonseca@gmail.com) (C. Fonseca).